Regensburg-based life-science company developing ingredients based on its IP-protected drug delivery technology OPTISOLV®
EVANIUM has raised €2.2M across 1 funding round from 3 investors, most recently a Seed round in Apr 2026. Based in Regensburg, Germany; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-04-15 | Seed | €2.2M |
| Angel Investors,Feast Ventures,FoodLabs |
| View deal → |
